Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2022-06-06 Director's Dealing
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
111年05月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed disclosure of shareholdings and pledged shares by company insiders, including directors and senior management, for the company 景岳生物科技股份有限公司. It lists share counts, pledged shares, and related ratios for various insiders. This type of document is a notification of personal share transactions or holdings by company directors and executives. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of voting results, nor a general regulatory filing. The content matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 2383 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement. Therefore, the correct classification is DIRS with high confidence.
2022-06-06 Chinese
111年年報及股東會資料 — 2022_3164_20220527F05.pdf
Annual Report Classification · 95% confidence The document is a detailed record of the 111th Annual General Meeting (AGM) of 景岳生物科技股份有限公司, held on May 27, 111 (Taiwan calendar year). It includes attendance details, chairman's speech, multiple agenda items such as the 110th fiscal year business report, audit committee review, approval of financial statements, profit distribution, and amendments to company bylaws. It also contains voting results for each agenda item. Additionally, the document includes attachments such as the 110th fiscal year business report, audit committee review report, and the auditor's report with financial statements. The presence of detailed financial statements and audit reports within the document indicates it is the actual annual report content rather than just an announcement or minutes. The document is comprehensive, over 15,000 characters, and contains substantive financial data and analysis for the full fiscal year 110, consistent with an Annual Report (10-K) filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2021
2022-06-02 Chinese
111年年報及股東會資料 — 2022_3164_20220527F14.pdf
Regulatory Filings Classification · 95% confidence The document is a detailed procedural guideline from a company regarding the acquisition or disposal of assets, including securities, real estate, equipment, intangible assets, and derivative products. It references specific laws such as the Securities Exchange Act and regulations from the Financial Supervisory Commission. The content includes internal control procedures, valuation requirements, board approvals, and risk management related to asset transactions. There is no indication that this is an announcement or a summary of a report, nor does it contain financial statements or earnings data. It is not a transcript, nor a voting result, nor a remuneration or governance report. The document is a regulatory compliance and procedural manual related to asset transactions and internal controls, which fits best under Regulatory Filings (RNS) as it is a compliance document that does not fit other specific categories.
2022-06-02 Chinese
111年年報及股東會資料 — 2022_3164_20220527F17.pdf
Major Shareholding Notification Classification · 95% confidence The document lists the top ten shareholders of the company 景岳生物科技股份有限公司, including their shareholdings and relationships among them (e.g., spouse, siblings). This type of information is typically disclosed in filings related to major shareholding notifications or shareholder structure disclosures. The document does not contain financial statements, management discussion, or meeting results. It is a notification of share ownership details and relationships among major shareholders, which aligns with the category 'Major Shareholding Notification' (MRQ). The document length is short and focused solely on shareholding information, confirming it is not a full report or announcement of a meeting result.
2022-06-02 Chinese
111年年報及股東會資料 — 2021_3164_20220527F04.pdf
Annual Report Classification · 100% confidence The document is titled as an "年度年報" which translates to "Annual Report". It includes detailed sections such as shareholder reports, company governance, financial and operational data, capital and shareholding information, and auditor details. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial, governance, and operational information aligns with the characteristics of an official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-06-02 Chinese
111年年報及股東會資料 — 2022_3164_20220527F02.pdf
AGM Information Classification · 95% confidence The document is a detailed shareholder meeting manual (議事手冊) for the Annual General Meeting (AGM) of GenMont Biotech Inc. It includes the agenda, reports, and attachments such as the 110年度營業報告書 (Annual Business Report for the year 110), the audit committee's review report, the auditor's report, and the 110年度財務報表 (financial statements for the year 110). The document contains comprehensive financial data, management reports, audit opinions, and corporate governance materials typically presented at an AGM. The presence of the full financial statements and audit reports within the document indicates it is not merely an announcement but the actual report materials used for the AGM. Therefore, the document fits best under the category of AGM Information (AGM-R), as it is the meeting materials and presentations shared during the Annual General Meeting, including the annual report and audit reports as attachments.
2022-06-02 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.